Tag:
Ilaris
Latest Headlines
Latest Headlines
FDA experts reject Novartis gout drug
A solid majority of the experts sitting on an FDA advisory committee has turned thumbs down on Novartis's application for the gout therapy Ilaris, citing safety concerns. But the 11-1 rejection
Novartis aims for gout indication for Ilaris
Novartis is looking to broaden use of its Ilaris drug beyond the rare-disease indication it already has. As the Wall Street Journal notes, the move is an example of Novartis' drug-development
Novartis gins promising data for late-stage gout drug
One of Novartis's top blockbuster hopefuls registered promising data in two pivotal trials for gout, offering supportive data for a string of regulatory filings in Europe and the U.S. ACZ885--an
Novartis' Vasella focuses on rare disease strategy
The recent approval of Novartis' Ilaris for a rare inflammatory disease marks one of the first solid commercial successes for CEO Daniel Vasella's long quest to overhaul the pharma company's
FDA approves Novartis' Ilaris for rare disease
The FDA has approved Novartis' Ilaris (also known as canakinumab or ACZ885), a treatment for children and adults with cryopyrin-associated periodic syndrome (CAPS). CAPS is a rare auto-inflammatory
